Vimarsana
Biggest News Aggregation in the World

Page 4 - Realtime Dynamix News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Realtime Dynamix. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Realtime Dynamix Today - Breaking & Trending Today

Aided by "Clean" FDA Label, US Dermatologists Report BMS' Sotyktu Has Potential to Delay Biologic Treatment in Plaque Psoriasis, According to Spherix Global Insights - Vimarsana News

Aided by "Clean" FDA Label, US Dermatologists Report BMS' Sotyktu Has Potential to Delay Biologic Treatment in Plaque Psoriasis, According to Spherix Global Insights

/PRNewswire/ -- On September 9, 2022, BMS announced the FDA approval of Sotyktu for moderate-to-severe plaque psoriasis (PsO), making it the first selective...

The European Medicines Agency's Updated Guidelines for JAK Inhibitors in Rheumatoid Arthritis - A Cause for Concern? Spherix Investigates - Vimarsana News

The European Medicines Agency's Updated Guidelines for JAK Inhibitors in Rheumatoid Arthritis - A Cause for Concern? Spherix Investigates

/PRNewswire/ -- On October 28, 2022, the European Medicines Agency's (EMA) safety committee (PRAC) announced recommendations to minimize the risk of serious...

FibroGen/Astellas' EVRENZO (roxadustat) Gaining Traction in the United Kingdom and Germany, according to Spherix Global Insights - Vimarsana News

FibroGen/Astellas' EVRENZO (roxadustat) Gaining Traction in the United Kingdom and Germany, according to Spherix Global Insights

/PRNewswire/ -- After a regulatory debacle in the United States which ended with FibroGen and AstraZeneca receiving a Complete Response Letter in August 2021...

FibroGen/Astellas' EVRENZO (roxadustat) Gaining Traction in the United Kingdom and Germany, according to Spherix Global Insights - Vimarsana News

FibroGen/Astellas' EVRENZO (roxadustat) Gaining Traction in the United Kingdom and Germany, according to Spherix Global Insights

/PRNewswire/ -- After a regulatory debacle in the United States which ended with FibroGen and AstraZeneca receiving a Complete Response Letter in August 2021...

Further Education Needed for the Proper Diagnosis of Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis in the EU5, Spherix Global Insights Reports - Vimarsana News

Further Education Needed for the Proper Diagnosis of Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis in the EU5, Spherix Global Insights Reports

/PRNewswire/ -- Rheumatologists in the EU5 (France, Germany, Italy, Spain, and the United Kingdom) recognize a disconnect in the diagnosis and referral process...